APT's mission is to develop an effective treatment that will safely prolong pregnancy, allowing babies more time to develop in the womb. Treatment with the TAC-PE will potentially extend the duration of pregnancy, thereby reducing the risk of lifelong disabilities in babies resulting from prematurity and IUGR.
APT has several patents either granted or pending that cover a broad range of apheresis technology for the treatment of preeclampsia. Dr. Henry Smith and Dr. James Smith, the inventors of the technology, are the first individuals to propose the removal of sFlt-1 using an apheresis method for the treatment of preeclampsia.
The Company holds exclusive rights to the following intellectual property (partial list):
US 20100247650 A1 - Treatment for pre-eclampsia in pregnant women using targeted apheresis
62/602,816 - Apheresis to treat high blood pressure in pre-eclampsia and hypertension (patent pending)
62/605,128 - Targeted apheresis to remove harmful substances from blood (patent pending)
APT’s founders continue to innovate new technologies and have additional patents pending (unpublished). APT believes that its innovative device designs and associated trade secrets will provide APT with an enduring competitive edge.